1Acute Medicine Department, Princess Royal University Hospital, King’s college trust, London BR6 8ND, UK
2Radiology Department, Princess Royal University Hospital, King’s College trust, London BR6 8ND, UK
American Journal of Medical Case Reports.
2021,
Vol. 9 No. 8, 424-427
DOI: 10.12691/ajmcr-9-8-10
Copyright © 2021 Science and Education PublishingCite this paper: Silfat Azam, Abdalla Khalil, Ahmad Taha. Guillain-Barré Syndrome in a 67-year-old Male Post COVID-19 Vaccination (Astra Zeneca).
American Journal of Medical Case Reports. 2021; 9(8):424-427. doi: 10.12691/ajmcr-9-8-10.
Correspondence to: Abdalla Khalil, Acute Medicine Department, Princess Royal University Hospital, King’s college trust, London BR6 8ND, UK. Email:
abdallak59@gmail.comAbstract
Since the COVID-19 pandemic has started in December 2019, millions of people have been infected all over the world and few vaccines have been invented recently. Extremely rare, Guillain-Barre Syndrome (GBS) was reported as a neurological complication after H1N1 flu vaccination. Currently, Pfizer and AstraZeneca vaccines are available to prevent infection with COVID-19. The first case of post-COVID-19 vaccine GBS has been detected in a secondary care hospital after vaccination with AstraZeneca. A 67-year-old man presented with an acute progressive ascending flaccid symmetrical motor neuropathy, and bilateral facial weakness which developed two weeks after receiving the first dose of AstraZeneca COVID-19 vaccine. His cerebrospinal fluid findings, nerve conduction result, and MRI brain result were all in favour of GBS diagnosis. The patient’s workup for all known infections associated with immune-mediated GBS was negative.
Keywords